Cover Image
市場調查報告書

乾癬治療藥的開發平台分析

Psoriasis Therapeutics Pipeline Analysis 2017

出版商 P&S Market Research Pvt. Ltd 商品編碼 590169
出版日期 內容資訊 英文 301 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乾癬治療藥的開發平台分析 Psoriasis Therapeutics Pipeline Analysis 2017
出版日期: 2017年10月01日 內容資訊: 英文 301 Pages
簡介

本報告提供乾癬治療藥的開發平台的相關調查,各階段、分子類型、給藥途徑、企業分析,臨床試驗的檢討,SWOT分析,及主要企業簡介等資訊。

第1章 調查背景

第2章 調查手法

第3章 摘要整理

第4章 開發平台的展望

  • 概要
  • 主要的促進要素
  • 主要的障礙
  • 乾癬治療藥的開發平台分析

第5章 乾癬治療藥的開發平台分析:各階段

  • 已提交:藥物簡介
  • 階段III:藥物簡介
  • 階段II:藥物簡介
  • 階段I:藥物簡介
  • 前臨床:藥物簡介
  • 藥物研發:藥物簡介
  • 不明:藥物簡介

第6章 臨床試驗檢討

  • 臨床試驗:各地區
  • 臨床試驗:各檢測狀況

第7章 競爭情形

  • 乾癬治療藥開發平台的主要企業基準
  • 乾癬治療開發平台的SWOT分析

第8章 企業簡介

第9章 附錄

目錄

Psoriasis therapeutics pipeline in 2017

The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person's immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of the skin, causing patches of psoriasis to appear. There are five types of psoriasis namely, plaque psoriasis or psoriasis vulgaris, guttate psoriasis, inverse psoriasis or flexural psoriasis or intertriginous psoriasis, pustular psoriasis, and erythrodermic or exfoliative psoriasis.

Insights on pipeline segments

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by topical route.

PAD technology platform for psoriasis drug development

MC2 Therapeutics A/S is using PAD technology platform for the development of MC2-01 for the treatment of psoriasis. PAD technology platform offers a number of unique advantages in the development of new topical drugs. PAD vehicles are special made oil-in-water dispersions in which the internal oil phase is stabilized by encapsulation in a thin yet robust aqueous film of surfactants.

Various collaborations for psoriasis drug development

Boehringer Ingelheim GmbH and AbbVie, Inc. entered in a worldwide agreement to develop and commercialize BI 655066, for the treatment of psoriasis.

Some of the key players developing drugs for the treatment of psoriasis include Amgen Inc., Maruho Co., Ltd., Boehringer Ingelheim GmbH and others.

Psoriasis Therapeutics Pipeline Analysis

By Phase

By Molecule Type

By Route of Administration

By Company

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope

1.3.1. Pipeline Analysis by Phase

1.3.2. Pipeline Analysis by Molecule Type

1.3.3. Pipeline Analysis by Route of Administration

  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By industry participants

2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Overview
    • 4.1.1 Signs and Symptoms
    • 4.1.2 Pathophysiology
    • 4.1.3 Epidemiology
    • 4.1.4 Diagnosis
    • 4.1.5 Treatment
  • 4.2 Key Drivers
  • 4.3 Key Barriers
  • 4.4 Psoriasis Therapeutics Pipeline Analysis
    • 4.4.1 Pipeline Analysis by Phase
    • 4.4.2 Pipeline Analysis by Molecule Type
    • 4.4.3 Pipeline Analysis by Route of Administration
    • 4.4.4 Pipeline Analysis by Company

Chapter 5. Psoriasis Therapeutics Pipeline Analysis by Phase (2017)

  • 5.1 Filed: Drug profiles
    • 5.1.1 Pre-Clinical Study
    • 5.1.2 Pre-Clinical Results
    • 5.1.3 Clinical Trials
    • 5.1.4 Clinical Results
    • 5.1.5 Strategic Development
    • 5.1.6 Designation
    • 5.1.7 Grants
    • 5.1.8 Patent
    • 5.1.9 Technology
  • 5.2 Phase III: Drug profiles
    • 5.2.1 Pre-Clinical Study
    • 5.2.2 Pre-Clinical Results
    • 5.2.3 Clinical Trials
    • 5.2.4 Clinical Results
    • 5.2.5 Strategic Development
    • 5.2.6 Designation
    • 5.2.7 Grants
    • 5.2.8 Patent
    • 5.2.9 Technology
  • 5.3 Phase II: Drug profiles
    • 5.3.1 Pre-Clinical Study
    • 5.3.2 Pre-Clinical Results
    • 5.3.3 Clinical Trials
    • 5.3.4 Clinical Results
    • 5.3.5 Strategic Development
    • 5.3.6 Designation
    • 5.3.7 Grants
    • 5.3.8 Patent
    • 5.3.9 Technology
  • 5.4 Phase I: Drug profiles
    • 5.4.1 Pre-Clinical Study
    • 5.4.2 Pre-Clinical Results
    • 5.4.3 Clinical Trials
    • 5.4.4 Clinical Results
    • 5.4.5 Strategic Development
    • 5.4.6 Designation
    • 5.4.7 Grants
    • 5.4.8 Patent
    • 5.4.9 Technology
  • 5.5 Pre-Clinical: Drug profiles
  • 5.6 Discovery: Drug profiles
  • 5.7 Unknown: Drug profiles

Chapter 6. Clinical Trials Review

  • 6.1 Clinical Trials by Region
  • 6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for Psoriasis Therapeutics Pipeline
  • 7.2 SWOT Analysis of Psoriasis Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Business Overview
  • 8.2 Product and Service Offerings

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.2 Related Reports

LIST OF TABLES

  • PIPELINE ANALYSIS OF PSORIASIS THERAPEUTICS, BY COMPANY (2017)
  • DESCRIPTION OF FILED DRUG CANDIDATES
  • CLINICAL TRIALS OF FILED DRUG CANDIDATES
  • DESCRIPTION OF PHASE III DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE III DRUG CANDIDATES
  • DESCRIPTION OF PHASE II DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE II DRUG CANDIDATES
  • DESCRIPTION OF PHASE I DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE I DRUG CANDIDATES
  • DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES
  • DESCRIPTION OF DISCOVERY DRUG CANDIDATES
  • DESCRIPTION OF UNKNOWN DRUG CANDIDATES
  • COMPANIES- AT A GLANCE

LIST OF FIGURES

  • RESEARCH METHODOLOGY
  • SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • PATHOPHYSIOLOGY OF PSORIASIS
  • PSORIASIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
  • PSORIASIS THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
  • PSORIASIS THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
  • BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • KEY PLAYERS BENCHMARKING FOR PSORIASIS THERAPEUTICS PIPELINE
  • SWOT ANALYSIS OF PSORIASIS THERAPEUTICS PIPELINE
Back to Top